Selected secondary clinical outcomes up to 6 months after randomization in the Remote IMPACT study
| Outcome | Group; no. (%) of patients | RR (95% CI) | |
|---|---|---|---|
| RIPC n = 128 | Sham n = 130 | ||
| Myocardial infarction | 32 (25.0) | 24 (18.5) | 1.35 (0.85 to 2.17) |
| Acute kidney injury* | |||
| Any | 27 (22.1) | 25 (20.2) | 1.10 (0.68 to 1.78) |
| Mild | 11 (9.0) | 15 (12.1) | |
| Moderate | 8 (6.6) | 8 (6.5) | |
| Severe, including acute dialysis | 8 (6.6) | 2 (1.6) | |
| Acute dialysis | 6 (4.9) | 1 (0.8) | |
| Stroke | 6 (4.7) | 6 (4.6) | 1.02 (0.34 to 3.07) |
| Death | 13 (10.2) | 9 (6.9) | 1.47 (0.65 to 3.31) |
Note: CI = confidence interval, RIPC = remote ischemic preconditioning, RR = relative risk.
↵* Excluding patients who underwent preoperative dialysis. Sample sizes for this outcome were 122 patients in the RIPC group and 124 patients in the sham group. Mild = increase in serum creatinine of 150% to 200% or increase of at least 26.4 μmol/L; moderate = increase in serum creatinine of greater than 200% up to 300%; severe = increase in serum creatinine greater than 300% or increase to level greater than 354 μmol/L, with an acute increase of at least 44 μmol/L, or need for acute dialysis.22 These are mutually exclusive categories, and the most severe category that a patient fulfilled was used.